AstraZeneca and Amgen achieve a late-stage success for Tezspire in treating esophagitis, paving the way for another FDA submission. This follows the drug's recent expansion into chronic rhinosinusitis, enhancing its therapeutic profile.
AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning another FDA submission for the asthma drug, which received an expansion into chronic rhinosinusitis last year.
Original title: “AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis”